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gens (5 patients). Conclusion: The MDmulticard Basic 
Extended Phenotype met the criteria prescribed for the 
testing of donor, patient, DAT-positive, and newborn 
samples in transfusion laboratory routine.
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Introduction
Traditional strategies for blood typing in routine clinical analy-
sis include techniques such as slide method, tube testing, micro-
plate technology, and column agglutination technique. Most of the 
blood typing techniques are based on specific antibody-antigen re-
actions on the erythrocyte surface [1], and nearly all of them are 
based on the formation of agglutinates [2]. However, there are 
limitations associated with conventional methods, including the 
availability of rare antisera as well as blood typing of recently trans-
fused patients and for those having a positive direct antiglobulin 
test (DAT-positives), e.g. patients with autoantibodies.
Molecular techniques have become a crucial tool in highlighting 
occasional blood group phenotyping errors. In particular, a num-
ber of weak phenotypes, previously typed false-negative, were dis-
covered in several blood group systems [3]. Even so, blood typing 
in emergency or life-threatening situations, where patients must be 
attended to quickly, would require special tools [4]. 
The Grifols MDmulticard® card, based on the lateral flow tech-
nology [5], is specifically designed to simplify standard methods 
and to optimize the workflow in extreme situations [6]. Unlike 
conventional methods, the MDmulticard involves little user inter-
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Summary
Background: Transfusion emergencies and critical situa-
tions require specifically designed devices to simplify 
and optimize the standard procedures. In addition, 
matching antigens over and above ABO-Rh-K would be 
beneficial. Methods: Routine blood samples were col-
lected in four immunohematology centers and tested 
with the new MDmulticard Basic Extended Phenotype 
for the simultaneous detection of the Duffy, Kidd, and Ss 
antigens, according to the principle of the lateral flow. 
Results were compared with those obtained using rou-
tine serology methods. Discrepancies were analyzed by 
molecular techniques/genotyping. Results: 310 samples 
were tested (167 donors; 75 patients; 28 subjects with 
positive direct antiglobulin test (DAT); 15 newborns; 25 
previously transfused patients). The 285 samples with 
non-mixed-field reaction yielded 1,710 antigen results 
with 8 discrepancies (0.47%) six of which in DAT-positive 
subjects: three false-positive (Fya) for MDmulticard, and 
two false-positive (Fya) plus three false-negative (Fyb) for 
the reference methods (MDmulticard PPA for donors/pa-
tients/newborns: 99.82%; negative percent agreement: 
100%; sensitivity: 100%; specificity: 99.39%, positive pre-
dictive value: 99.75%; negative predictive value: 100%). 
The MDmulticard detected mixed-field in 15 antigen re-
actions from 13 transfused patients, undetected by the 
comparative method, with the opposite result in 8 anti-
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vention; so the possibility of error during processing or interpreta-
tion of results is greatly reduced. Preliminary data indicate that the 
MDmulticard allows determining a patient’s ABO group, Rh phe-
notype and Kell (K) in around 5 min with a single drop of blood 
[7], with a very low minimum sample volume required (25 μl) 
which may also be adequate for the typing of newborns. 
Even in a transfusion emergency, extending phenotype match-
ing to antigens in addition to ABO, Rh and K would be beneficial 
in reducing alloimmunization [8–10]. With this aim, the new MD-
multicard Basic Extended Phenotype is intended to perform a basic 
extended phenotype covering additional clinically significant anti-
gens: Duffy (Fya, Fyb), Kidd (Jka, Jkb), and Ss antigens (S, s) [11]. 
Pilot studies indicate that MDmulticard Basic Extended Phenotype 
allows for simple and reliable testing of all these antigens together 
in around 5 min [12]. In addition, MDmulticard Basic Extended 
Phenotype may be useful to confirm weak phenotypes, including 
Fyx, a weak variant of Fyb [12] as well as for typing patients with a 
positive DAT [13].
In this study, the performance of the MDmulticard Basic Ex-
tended Phenotype was compared to the routine state-of-the-art 
methods of four reference immunohematology centers. 
Material and Methods
This was a multicenter study conducted at four European immunohematol-
ogy centers in France (Valenciennes), Germany (Berlin, Ulm) and Spain (Mur-
cia), aimed to evaluate the MDmulticard Basic Extended Phenotype (Medion 
Grifols Diagnostics, Düdingen, Switzerland) performance, reliability, usability, 
and adaptability to real-world transfusion laboratory routines. The operators 
had good knowledge and understanding of the MDmulticard Basic Extended 
Phenotype product and were well-trained in its use.
The study was conducted in compliance with a clinical protocol, regulatory 
requirements, good clinical practice (GCP), and the ethical principles of the lat-
est revision of the Declaration of Helsinki as adopted by the World Medical 
Association. All data and information collected during this study was consid-
ered and treated as confidential.
Blood Sampling
Anticoagulated samples (whole blood, erythrocyte sediment or clotted 
blood, as needed) from donors, patients (not transfused within 3 months prior 
to this study) and newborns (cord blood) were collected and included in the 
evaluation. Blood samples not used immediately were stored at 2–8  ° C. The 
samples had to have known Duffy, Kidd and Ss antigens, either by being taken 
from a serum archive or being previously tested with the routine method. A 
minimum of 240 evaluated samples (±10% accepted) during a period of 3–4 
weeks was expected. 
Also, a number of complex samples were included: reactive DAT-positive 
samples collected from patients with known autoantibodies (only samples react-
ing ˰2+ positive with anti-IgG ± anti-C3d, anti-IgM, anti-IgA were included), 
and ‘mixed-field’ samples (two erythrocyte populations) obtained from patients 
who had been transfused within a few days to 3 months prior to the study with 
random (not selected for Duffy, Kidd and Ss antigens) red blood cells.
Study Device
The MDmulticard Basic Extended Phenotype is a card reagent formulated 
using monoclonal antibodies that allows the simultaneous detection of the 
Duffy (Fya [FY1], Fyb [FY2]), Kidd (Jka [JK1], Jkb [JK2]), and Ss antigens (S 
[MNS3], s [MNS4]) according to the principle of the lateral flow. The device 
has a core area of application with two detection fields impregnated with the 
respective antibodies, as well as two detection zones containing a control spot 
(ctl) and a process control point (val). Ctl allows for each test to verify whether 
the red blood cells are reacting with any of the components included in the dif-
ferent antibody formulations, whereas val allows for each test to verify whether 
i) blood was added, and ii) the flow characteristics of the test are correct. Results 
are immediately documented as negative reaction (no band) or a positive reac-
tion (red band). Positive reaction strength is graded according to the manufac-
turer’s instructions for use (IFU) of MDmulticard Basic Extended Phenotype: 
3+ (arrow-shaped band), 2+ (normal band), 1+ (weak band), and mixed-field 
reaction (half band). Figure 1 illustrates some of these features in real pictures. 
MDmulticard Basic Extended Phenotype Procedures
All MDmulticard Basic Extended Phenotype tests were performed accord-
ing to the manufacturer’s IFU. Suspensions to be read by the MDmulticard 
Basic Extended Phenotype were prepared as follows: 
For whole blood samples, one drop (50 μl) of anticoagulated whole blood 
was mixed with four drops (200 μl) of Diluent F (Medion Grifols Diagnostics) 
in a test tube; for erythrocyte sediment samples, one drop (50 μl) of sediment 
blood was mixed with eight drops (400 μl) of Diluent F in a glass test tube; for 
clotted blood samples, serum was removed, e.g. by aspirating with a Pasteur pi-
pette, leaving a small amount of serum in the tube. After mild stirring, two 
drops (100 μl) of liquid from the blood clot were drawn and mixed with two 
drops (100 μl) of Diluent F in a test tube. In all cases, two drops (100 μl) of the 
resulting suspension were added to the application zone of the MDmulticard 
Basic Extended Phenotype. After 30 s, six drops of Diluent F were added to the 
application zone. After 4 min, six additional drops (300 μl) of Diluent F were 
added to the application zone. The results were read and recorded after 4 min 
(8.5 min after application of the suspension to the card).
Comparative Methods
The routine methods used in each of the participating centers were as 
follows: 
Valenciennes laboratory: Erythrocytes Magnetized Technology (E.M.® 
Technology) on Qwalys® (Diagast, Loos, France) for patient, donor, newborn 
Fig. 1. Positive reac-
tions as they occur in 
the MDmulticard Basic 
Extended Phenotype: 
A) strong reaction 3+ 
(arrow-shaped band) 
in Fyb; B) weak reac-
tion 1+ (weak band) in 
Fya; and C) mixed-field 
reaction (half band) in 
Fya and S.
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and DAT-positive samples; conventional tube test method (Immucor Gamma; 
Immucor, Norcross, GA, USA) for mixed-field samples. 
Ulm laboratory: Conventional tube test method (Immucor Gamma for Fya, 
Fyb, and s phenotypes; Diagnostic Grifols, Barcelona, Spain, for Jka and Jkb phe-
notypes; Bio-Rad Laboratories Inc, Hercules CA, USA, for S phenotype). All 
samples with positive DAT and transfused patient samples were also genotyped 
using RBC-Ready Gene kits MNS and KKD (Inno-Train Diagnostik GmbH, 
Kronberg, Germany), DNA extracted with QIAmp DNA Mini Kit (Qiagen 
GmbH, Hilden, Germany). 
Berlin laboratory: Automated blood grouping technology such as solid 
phase (NEO®; Immucor) for patient and newborn samples; automated 
(Erytra®) and manual gel column agglutination (Diagnostic Grifols) for donor 
samples and transfused patient samples, respectively. Samples with positive 
DAT and with mixed-field reaction were analyzed after DNA extraction by 
PCR-SSP technology (BAG, Lich, Germany). 
Murcia laboratory: Solid-phase microplate (Capture-R® Select®; Immucor) 
for donor samples. In patients and samples from pipe segments of donation 
bags, glass beads column agglutination (BioVue®; Ortho-Clinical Diagnostics, 
Raritan, NJ, USA) were used for samples with Fya, Fyb, s phenotypes; conven-
tional tube testing with liquid antisera (Immucor Gamma) were used for sam-
ples with Jka, Jkb and S phenotypes. 
Data Analysis
The results obtained with the MDmulticard Basic Extended Phenotype were 
compared with those obtained with the reference methods. In samples with 
non-mixed-field reaction (all but those from transfused patients), a difference 
of interpretation (positive / negative) was considered a discrepancy. In case of 
discrepancy or unclear results (i.e. doubtful readings, unreadable results, or 
mixed-field reaction) the test with the MDmulticard Basic Extended Phenotype 
was repeated to confirm the result. Discrepancies were resolved by molecular 
techniques/genotyping in favor of one system or another (excepting in those 
DAT-positive samples already compared to genotyping as the reference 
method) and were classified as number of false-positives (FP), true-positives 
(TP), false-negatives (FN) and true-negatives (TN) as appropriated. 
Reaction results from donor, patient, and newborn samples comparing 
MDmulticard Basic Extended Phenotype and reference methods were evaluated 
in terms of positive percent agreement (PPA), negative percent agreement 
(NPA), and overall percent agreement (OPA). All matching percentages were 
followed by the 95% confidence intervals (CI). For phenotyping (donors, pa-
tients, and newborns), the acceptance criteria for PPA and NPA were set at the 
lower 95% confidence bound to be >99%. Results of performance after analysis 
of discrepancies were evaluated in terms of sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV).
In samples from transfused patients with mixed-field reactions, analysis of 
the comparison of MDmulticard Basic Extended Phenotype and serology refer-
ence methods was descriptive. Differential results between methods were not 
considered discrepancies, although all samples were also tested with 
genotyping.
Results
A total of 310 samples were collected (Berlin: 96; Ulm: 95; Mur-
cia: 74; Valenciennes: 45) and were evaluated with MDmulticard 
Basic Extended Phenotype: 167 (53.9%) from donors, 75 (24.2%) 
from not previously transfused patients, 25 (8.1%) from previously 
transfused patients, 28 (9.0%) from DAT-positive patients, and 15 
(4.8%) from newborns. 
Non-Mixed-Field Samples
Results of the MDmulticard Basic Extended Phenotype test ob-
tained in the 285 samples with non-mixed-field reaction (all but 
those from previously transfused patients) are shown in table  1. 
That represented 1,710 antigen results (1,002 from donors, 450 
from patients, 90 from newborns and 168 from DAT-positives). 
Comparison with a reference method was not available in two 
DAT-positive samples.
A total of eight discrepancies (in eight samples, six of them 
DAT-positive) between the antigen detection results of MDmulti-
card Basic Extended Phenotype and the reference method were ob-
served (0.47% of the tests and 2.8% of the samples). Three of the 
discrepancies were in Fya positivity, two in Fya negativity, and 
three in Fyb positivity (tables 1 and 2). 
Antigen Reaction result Sample origin
donors patients newborns DAT-positive total
Fya + 105 53  8 17c 183
−  62 22  7 11 (9)b 102
Fyb + 129a 57 13a 27 (25)a 226
−  38 18  2  3 (1)  59
Jka + 127 57 12 22 (21) 218
−  40 18  3  6 (5)  67
Jkb + 117 49 10 19 (17) 195
−  50 26  5  9  90
S +  87 44 10 15 (14) 156
−  80 31  5 13 (12) 129
s + 149 56 11 24 (22) 240




Table 1. Antigen test results with MDmulticard 
Basic Extended Phenotype in non-mixed-field 
samples and discrepancies with respect to results 
obtained with reference methods (values in paren-
theses are results not taking into account two 




Transfus Med Hemother 2018;45:341–346344
All three discrepancies in Fya positivity were in DAT-positive 
samples, which showed a weak or very weak positive result with 
MDmulticard Basic Extended Phenotype (<+1 strength, noted as 
‘not negative’ by the performing technicians) and negative with the 
reference method (in this case, genotyping). In all three samples, 
Fya was confirmed to be negative, thus resulting in FP for MDmul-
ticard Basic Extended Phenotype. 
Of the three discrepancies in Fyb positivity (one donor, one 
newborn, one DAT-positive), all of them showed a weak positive 
result with MDmulticard Basic Extended Phenotype and were neg-
ative with the reference method (tube testing). Genotyping re-
vealed the presence of FY*X allele which causes a weak positive Fyb 
phenotype. The MDmulticard Basic Extended Phenotype results 
were therefore correct (TP).
In the two samples typed Fya-negative by the MDmulticard 
Basic Extended Phenotype but positive by the reference method 
(tube testing), both in DAT-positive samples, genotyping evi-
denced the lack of the FY*A allele. The MDmulticard Basic Ex-
tended Phenotype negative results were therefore correct (TN). 
Performance Results
Performance results of both MDmulticard Basic Extended Phe-
notype and comparison methods are summarized in table 3. 
With regard to the phenotyping results from donors, patients 
and newborns, PPA of MDmulticard Basic Extended Phenotype 
was 99.82% (95% CI 98.82–99.97%), NPA was 100% (95% CI 
99.65–100%) and OPA was 99.87% (95% CI 99.81–99.98%). 
Sensitivity of MDmulticard Basic Extended Phenotype was 
100% (95% CI 99.68–100%), specificity was 99.39% (95% CI 98.22–
99.79%), PPV was 99.75% (95% CI 99.27–99.92%) and NPV was 
100% (95% CI 99.22–100%).
Mixed-Field Samples
Results of the 150 antigen reactions detected in the 25 samples 
from transfused patients are summarized in table  4. Antigen with 
most mixed-field (two erythrocyte populations) reactions was S (n = 
8/22), whereas Jkb and s antigens had one mixed-field reaction each. 
Three samples had no result available with the reference method 
and were therefore excluded for comparison. Results are shown in 
table 5. 
In 4 of the 12 samples tested with gel column as comparator, 7 
antigens showed mixed-field agglutination that were not detected 
by the MDmulticard Basic Extended Phenotype (2 Fyb, 3 Jka, 1 Jkb, 
and 1 S), with reaction strength from weak to very weak in all cases. 
On the other hand, MDmulticard Basic Extended Phenotype de-
tected mixed-field agglutination in 9 antigens undetected by gel 
Table 2. Contingency table of antigen test reaction results with MDmulti-





+ 1,206   6 1,212
− 2 487 489
Total 1,208 493 1,701
Table 3. Performance results of antigen testing after analysis of discrepan-




+ 1,209 3 1,212
− 489 0 489
Total 1,698 3 1,701
Reference methods
+ 1,205 2 1,207
− 491 3 494
Total 1,696 5 1,701
Table 4. Results of mixed-field (MF) reactions (double population) using 




Fya  21 0 4
Fyb  22 0 3
Jka  19 1 5
Jkb  23 1 1
S  15 2 8
s  24 0 1
Total 124 4 22
Table 5. Comparison of MDmulticard Basic Extended Phenotype with se-
rology reference methods and genotyping in samples with mixed-field (MF) 
reactions (n = 22)
Comparison method MDmulticard 
+ − MF total
Gel column agglutination (n = 12)
+  49 0  6  55
−   4 0  3   7
MF   7 0  3  10
Total  60 0 12  72
Tube testing (n = 10)
+  50 0  0  50
−   0 3  6   9
MF   0 1  0   1
Total  50 4  6  60
Genotyping (n = 22)
+  90 0  1  91
−  20 4 17  41
MF N/A N/A N/A N/A
Total 110 4 18 132
N/A = Not applicable.
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column (1 Fya, 2 Fyb, 2 Jka, and 4 S) from 8 samples. Mixed-field 
reaction in 3 antigens (1 Fya and 2 Fyb) from 2 samples was de-
tected by both systems. 
In the 10 samples from transfused patients tested with tube 
technique as comparator, in one case (S) a mixed-field reaction was 
observed, which was not detected by the MDmulticard Basic Ex-
tended Phenotype. By contrast, MDmulticard Basic Extended Phe-
notype detected 5 mixed-field reactions in 6 antigens undetected 
by tube testing (1 Fyb, 2 Jka, 1 Jkb, 1 S, and 1 s) from 5 samples.
When comparing the results of the serological methods with the 
results of genotyping, full concordance was observed in only 5 
samples which were positive for all 6 antigens. Table 5 shows that 
serological methods tended to detect more positives (n = 110 for 
MDmulticard Basic Extended Phenotype, n = 105 for both refer-
ence methods) and fewer negatives (n = 4 for MDmulticard Basic 
Extended Phenotype, n = 16 for both reference methods) than true 
results predicted by genotyping (n = 91 and n = 41, respectively).
Discussion
The development and improvement of tools for rapid and relia-
ble blood typing adequate for use in acute clinical situations is war-
ranted [4]. In a step further to the MDmulticard that determines a 
patient’s main antigens (ABO, Rh phenotype and K) within a few 
minutes [7], the new MDmulticard Basic Extended Phenotype cov-
ers an additional array of clinically significant antigens [11] through 
the same lateral flow principle. Hence, the combination of typing 
reagents for Fy, Jk and Ss antigens on one test card would be very 
helpful for an easy and rapid phenotyping of red cell units or pa-
tients when the latter are to be transfused with blood compatible for 
Fy, Jk and Ss antigens, e.g. patients with warm reactive autoantibod-
ies or patients with sickle cell disease [14–16]. Furthermore, pheno-
typing is known to be challenging in these patients due to positive 
DAT and recent transfusions in many cases. We found that the 
MDmulticard Basic Extended Phenotype was as reliable as the rou-
tine reference methods of four immunohematology centers (except 
molecular techniques/genotyping, as could be expected).
Agreement (PPA, NPA, and OPA) between MDmulticard Basic 
Extended Phenotype and the reference methods in phenotyping re-
sults ranged between 99.8% and 100%. The >99% criteria for the 
lower 95% confidence bound was met for NPA (99.65%) and was 
close for PPA (98.82%). However, the two cases of discrepancy (1 
weak Fyb-positive in donors and 1 weak Fyb-positive in newborn 
samples) were resolved in favor of MDmulticard Basic Extended 
Phenotype. Both cases plus one more found in DAT-positives were 
caused by the presence of FY*X allele, which proved MDmulticard 
Basic Extended Phenotype to be highly sensitive to weak Fyb-posi-
tive compared to the reference method used (tube testing; E.M. 
Technology). A remarkable sensitivity of the MDmulticard for the 
detection of weak Fyb antigens has been reported recently [17]. The 
five remaining discrepancies were all observed in the testing of 
DAT-positive samples. The high sensitivity of the MDmulticard to 
detect weak Fyb antigens could be used to confirm the results of red 
cell units previously typed as Fyb-negative before transfusions of 
Fyb-negative patients.
DAT-positive samples are known to be challenging for most 
typing systems. The cells of patients with a strong reactive DAT 
(e.g., patients with autoantibodies and patients with sickle cell dis-
ease) often cause false-positive reactions, especially when typing is 
done by the indirect Coombs test [18]. False-positive reactions are, 
however, not restricted to IgG antisera. Recent studies revealed 
that IgM antisera also can be interfered by a reactive DAT [19]. 
The MDmulticard is based on the lateral flow technique and may, 
therefore, be less prone to interference by a reactive DAT. That was 
the case with 2 Fya-negative samples that were tested falsely posi-
tive by the tube method but truly negative by the MDmulticard 
Basic Extended Phenotype.
26 samples with reactive DAT were tested with the MDmulticard 
Basic Extended Phenotype. Two samples negative for Fya by PCR 
were tested falsely positive by the tube method, but reacted truly 
negative with the MDmulticard Basic Extended Phenotype. Three 
Fya-negative samples showed strongly positive reactions when tested 
by the gel column agglutination method but only weak or very weak 
reactions with the MDmulticard Basic Extended Phenotype. Weak 
reactions of lgG-coated red cells in the MDmulticard Basic Extended 
Phenotype may occur with the anti-Fya, which is the only monoclo-
nal antibody of the IgG type in the MDmulticard Basic Extended 
Phenotype [20]. These very weak false-positive bands could be easily 
distinguished from true positive bands or mixed-field bands. Thus, 
when typing patients with a reactive DAT for their FY phenotype, 
the MDmulticard Basic Extended Phenotype demonstrated a clear 
advantage over the indirect antiglobulin test (tube method or gel 
column method). So far, the only reliable determination of the FY 
phenotype of such patients can be done by genotyping. 
Compared to serological blood grouping, molecular methods 
still take longer, are more expensive, and are not established in 
every immunohematological laboratory [21]. The MDmulticard 
Basic Extended Phenotype might become an equal or even superior 
alternative for such purposes. Moreover, the MDmulticard system 
could not only be adequate for blood typing in emergency situa-
tions [4, 8–10] and extreme environment conditions [22], but 
could also be more cost-effective, as it limits the number of geno-
typing investigations necessary (and therefore the costs) to provide 
antigen-matched blood, especially for patients with autoantibodies 
or sickle cell disease. However, this should be confirmed by studies 
specifically aimed to cost and time analyses [23]. 
Globally, in all samples with non-mixed-field reaction, perfor-
mance of MDmulticard Basic Extended Phenotype was very good: 
100% sensitivity and NPV (no FN) and >99.3% specificity and PPV 
(3 FP in Fya). Although comparison with several quite different ref-
erence methods could be deemed as a limitation of the study, it 
should be pointed out that genotyping was taken as the focal point 
for all analyses. In addition, the number of analyzed samples was 
limited to those evaluable expected from routine practice in the 
immunohematology centers during the 1-month study period. 
Previously transfused patients are also challenging for typing 
systems. In fact, no routine phenotyping method is able to distin-
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guish between autologous and transfused red cells [24]. So far, only 
genotyping allows the prediction of the phenotype of a transfused 
patient. Depending on the number of transfused units and depend-
ing on the phenotypes of the transfused cells, the patients present 
with more or less pronounced mixed-field agglutination. In this 
study, neither the serology reference methods nor the MDmulticard 
Basic Extended Phenotype were able to overcome the hurdle of 
mixed-cell populations. Detection of mixed-field reaction in at least 
one antigen of the investigated samples will help the laboratory to 
identify transfused patients. In addition, if evidence of mixed-field 
reaction in one of the antigens is found, none of the other antigens 
tested by serological methods should be regarded as reliable/valid. 
Hence, in 15 samples out of the 22 tested and compared, the MD-
multicard Basic Extended Phenotype detected antigen-positive 
mixed-cell populations that were not detected by the comparative 
method, while the opposite result occurred in 8 samples. Although 
these results may suggest differential sensitivities of the tested 
methods for specimens collected from transfused patients, due to 
the small sample size, the significance of the current evaluation is 
limited and should be further investigated in a larger study. 
Sometimes a method with increased sensitivity may be advanta-
geous, e.g. when transfused cells are searched for. On the other 
hand, a method with lower sensitivity that overlooks small trans-
fused cell populations may be helpful when the phenotype of a 
transfused patient is to be estimated. It is suggested that every insti-
tution should perform an individual analysis to decide the most ap-
propriate sensitivity of the typing system [25]. Sometimes a nega-
tive antigen typing helps to confirm or refuse the specificity of an 
antibody, even in a transfused patient. 
In summary, overall performance and usability of the new MD-
multicard Basic Extended Phenotype in transfusion laboratory 
routine met the criteria prescribed for the testing of donor, patient, 
and newborn specimens. Moreover, MDmulticard Basic Extended 
Phenotype could be used in patients with positive DAT and in 
transfused patients with reliability similar to other routine sero-
logical methods. 
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